According to a recent LinkedIn post from Segmed, the company is actively participating in the European Congress of Radiology 2026 in Vienna, with a focus on advancing medical AI using structured, de-identified real‑world imaging data from diverse patient populations. The post highlights use cases such as AI algorithm training, external validation, medical device development, real‑world evidence generation, and multicenter performance benchmarking.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s presence in the AI Exhibition Hall and its multiple scientific contributions, including work on multimodal data, LLM benchmarking for CAD‑RADS scoring, and bias mitigation in AI, suggest an effort to position its data platform as a key infrastructure layer for clinical AI. For investors, this emphasis on validation, scalability, and trust in radiology AI could indicate a strategic push to deepen engagement with AI developers, device manufacturers, and regulators, which may support future revenue opportunities and strengthen Segmed’s role in the medical imaging data ecosystem.